This invention concerns the compounds of formula ##STR00001## the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R.sup.1 and R.sup.2 are each independently selected from hydrogen; hydroxy; amino; optionally substituted C.sub.1-6alkyl; C.sub.1-6alkyloxy; C.sub.1-6alkylcarbonyl; C.sub.1-6alkyloxycarbonyl; Ar.sup.1; mono- or di(C.sub.1-6alkyl)amino; mono- or di(C.sub.1-6alkyl)-aminocarbonyl; dihydro-2(3H)-furanone; or R.sup.1 and R.sup.2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-6alkyl)amino-C.sub.1-4alkylidene; R.sup.3 is hydrogen, Ar.sup.1, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl, C.sub.1-6alkyloxy-carbonyl, C.sub.1-6alkyl substituted with C.sub.1-6alkyloxycarbonyl; and R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently selected from hydrogen, halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is optionally substituted C.sub.1-10alkyl; C.sub.3-10alkenyl; C.sub.3-10alkynyl; C.sub.3-7cycloalkyl; Ar.sup.1 is optionally substituted phenyl; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.